Trial Profile
A Randomized, Double-blind, Parallel, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of Oral GW677954 Capsules (15 mg) in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Insulin (Primary) ; Sodelglitazar (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors GSK
- 19 Nov 2010 Planned number of patients changed from 116 to 1 as reported by ClinicalTrials.gov.
- 19 Nov 2010 Actual end date (Nov 2006) added as reported by ClinicalTrials.gov.
- 15 Oct 2008 Actual start date changed from Aug 2006 to Sep 2006 as reported by ClinicalTrials.gov.